
Singapore businesses dust off contingency plans following recent increase in COVID-19 cases
These include hiring more part-time workers, engaging sanitisation services and putting in place protective equipment for staff and customers.
Singapore's health authorities said on Tuesday (May 13) that the estimated number of COVID-19 cases rose to 14,200 in the week of Apr 27 to May 3, up from 11,100 cases in the previous week.
With more people falling ill, businesses like restaurants and transport firms told CNA they are looking to ensure they have adequate labour for their operational needs.
EXTRA HANDS IN THE KITCHEN
A seafood restaurant said two of its chefs fell ill from COVID-19, leaving the dining establishment understaffed ahead of the busy Mother's Day holiday period last week.
The House of Seafood, located in Punggol, looked to hire experienced part-time chefs to help cope with a full house of patrons as it battled an employee shortage.
Ms Feng Ying, a supervisor at the restaurant, told CNA that they sought temporary chefs that had similar experience to the ones that were ill.
She said this is to ensure that customers do not notice a drop in the quality and taste of the dishes sold by the restaurant, known for its crab offerings.
The supervisor added that it was not easy to find such skilled part-time staff during this hectic season.
'We need to raise the salary, by about 50 per cent more than usual, in order to hire them," said Ms Feng.
Other measures taken by the seafood eatery to deal with the rise in cases include extra sanitisation and disinfection efforts.
The House of Seafood has engaged sanitisation services to perform deep cleaning of kitchen equipment and common locations with a high volume of contact, like toilets and door handles.
It has also doubled the disinfection frequency for its premises to four times a day.
FLEXIBLE SCHEDULING
Meanwhile, transport firms like SG Bus Charter Travel & Tours have also increased sanitisation efforts and worked to ensure its drivers wear personal protective equipment.
The firm's director Dinesh Dhillon said the company has experience operating services during the pandemic, which began in 2020.
'We were actually involved in the transportation of people coming back from overseas, going for quarantine,' he said, recalling how drivers had to wear face shields and gloves in addition to other personal protective equipment.
Mr Dinesh added that their drivers currently wear N95 masks, a practice maintained since the pandemic.
He said these N95 masks are 'more than enough' for the present situation, and the company does not intend to install air purifiers onboard the buses for now.
The company's buses and vans are also sanitised twice a day.
With staffing levels a consideration in case of illness, Mr Dinesh said the company has flexible work protocols for its employees, such as requiring administrative staff to work from home if they are ill with COVID-19.
He said there is also a contingency plan should drivers also fall ill, allowing for quick workforce adjustment.
"We have a schedule on a day-to-day basis. When … two or three or maybe four or five drivers come down … we'll just reshuffle the whole schedule,' added Mr Dinesh, who said any reshuffling will not add more shifts to the company's drivers.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Straits Times
2 hours ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.


CNA
5 hours ago
- CNA
Asia First - Wed 13 Aug 2025
02:27:30 Min From the opening bell across markets in Southeast Asia and China, to the biggest business interviews and top financial stories, tune in to Asia First to kick-start your business day.


CNA
6 hours ago
- CNA
Getting residents to buy into VERS could be a challenge: Real estate analysts
Real estate analysts said it could be challenging to get residents to buy into the Voluntary Early Redevelopment Scheme, or VERS. Some said the government could make it more attractive by offering incentives, such as priority in purchasing a new flat. Residents of older estates have voiced concerns over compensation and affordability of flats in the area. As home owners have diverse needs, experts said sensitivity and prudence is required if VERS is to adequately address the impact of lease decay.